The rare blood clot condition that affected a small number of people who got the Johnson & Johnson COVID-19 vaccine is eight to 10 times more likely to occur from a COVID-19 infection than from the vaccine, according to a special report from the American Heart Association/American Stroke Association Stroke Council Leadership.
Here & Now s Robin Young speaks to the author of that special report,
Dr. Karen Furie, who is the neurologist in chief at Rhode Island Hospital and the chair of neurology at the Warren Alpert Medical School of Brown University.
This segment aired on May 5, 2021.
CORONAVIRUS
Rare blood clots up to 10 times more likely from COVID-19 infection than from Johnson & Johnson vaccine, report says
The chief of neurology at Lifespan Corporation says blood clots arenât the only long-term effects she has seen in patients who have had COVID-19.
By Alexa Gagosz Globe Staff,Updated May 3, 2021, 6:34 p.m.
Email to a Friend
The COVID-19 vaccine developed by the Janssen Pharmaceutical Companies of Johnson & Johnson, is at Rhode Island Hospital.Jonathan Wiggs/Globe Staff
PROVIDENCE â The same rare blood clot condition connected to the Johnson & Johnson COVID-19 vaccine is more of a risk following a COVID-19 infection, according to a newly released report.
Guidance on diagnosis and management of cerebral venous sinus thrombosis after a COVID-19 vaccine
Last Friday, the Centers for Disease Control and Prevention (CDC) and the U.S. Food & Drug Administration (FDA) lifted the pause in administration of the Johnson & Johnson (Janssen) COVID-19 vaccine in the U.S. The temporary pause was due to reports of a serious condition called cerebral venous sinus thrombosis (CVST), which refers to blood clots in the brain s veins - not in the arteries, as is the case for most strokes - in combination with thrombocytopenia (low blood platelet count).
CVST and thrombocytopenia together is called thrombosis-thrombocytopenia syndrome (TTS). When TTS is linked to receiving a COVID-19 vaccine, it is called vaccine-induced immune thrombotic thrombocytopenia (VITT). CVST has also been associated with cases of TTS in adults who received the AstraZeneca COVID-19 vaccine available in Europe, according to the European Medicines Agency, the agency responsible f
(Photo: Adobe Stock)
Many Americans have gained a staggering amount of weight since the coronavirus outbreak and the main culprit is stress. The phenomenon is being called
COVID-15, a play on the freshman fifteen which is an unexpected weight gain during one’s first year in college, but if only the weight gain was just 15 pounds.
According to a recent survey conducted by the American Psychological Association (APA), 61% of Americans reported undesired weight gain or loss since the World Health Organization (WHO) declared COVID-19 a pandemic.
The poll, which surveyed 3,103 people, found that two in five participants gained more weight than they intended, with an average increase of 29 pounds. Of those who reported weight gain, 1 in 10 said they had gained 50 pounds or more.
E-Mail
DALLAS, April 29, 2021 – Last Friday, the Centers for Disease Control and Prevention (CDC) and the U.S. Food & Drug Administration (FDA) lifted the pause in administration of the Johnson & Johnson (Janssen) COVID-19 vaccine in the U.S. The temporary pause was due to reports of a serious condition called cerebral venous sinus thrombosis (CVST), which refers to blood clots in the brain’s veins - not in the arteries, as is the case for most strokes - in combination with thrombocytopenia (low blood platelet count). CVST and thrombocytopenia together is called thrombosis-thrombocytopenia syndrome (TTS). When TTS is linked to receiving a COVID-19 vaccine, it is called vaccine-induced immune thrombotic thrombocytopenia (VITT). CVST has also been associated with cases of TTS in adults who received the AstraZeneca COVID-19 vaccine available in Europe, according to the European Medicines Agency, the agency responsible for the scientific evaluation, supervision and safety of medic